ArticleIndian pediatrics2026
Clinical Course and Predictors of Metabolic Dysfunction Associated Steatotic Liver Disease in Obese Children and Adolescents.
Article in Indian pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Adolescent Obesity: A Stepwise Clinical Approach.Indian journal of pediatrics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate the course and predictors of outcome of metabolic dysfunction-associated steatotic liver disease (MASLD).
methodsRecords of 100 obese children with MASLD were reviewed for change in body mass index (BMI) and alanine aminotransferase (ALT) levels.
resultsA total of 100 (73 boys) children with mean (SD) age 12.1 (2.8) years followed for 2.0 (1.6) years were included. Normalization in ALT levels occurred in 72 (72%) at 1.1 (0.8) years of follow-up; 17 (23.6%) relapsed after 1.6 (1.3) years. Sustained remission (n = 55; 55%) was associated with greater BMI Z-score reduction (%) [median (q1, q3) 15.3 (5.1, 25.5) vs. 3.4 (- 4.3, 11.1); P < 0.001]. Multivariate regression identified BMI Z-score reduction as the only predictor of remission (OR 6.67, 95%CI 1.54-33.3; P = 0.007). ROC analysis showed BMI Z-score reduction of 13.8% predicted remission with an area under curve of 0.72 (95%CI: 0.62, 0.82; P < 0.001).
conclusionPediatric MASLD has a variable course, with remission dependent on the reduction in BMI Z-score.
Indexed as
Identifiers
41701310What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.